Enabling GLP-1 Commercial Success through Drug Device Readiness

  • Drug–device readiness is now a commercial differentiator for GLP-1s
  • An integrated Formulation Development–DP–device model reduces risk and timelines
  • Early device strategy unlocks scalable growth